326 related articles for article (PubMed ID: 30196913)
21. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
[TBL] [Abstract][Full Text] [Related]
22. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Bakouny Z; Braun DA; Shukla SA; Pan W; Gao X; Hou Y; Flaifel A; Tang S; Bosma-Moody A; He MX; Vokes N; Nyman J; Xie W; Nassar AH; Abou Alaiwi S; Flippot R; Bouchard G; Steinharter JA; Nuzzo PV; Ficial M; Sant'Angelo M; Forman J; Berchuck JE; Dudani S; Bi K; Park J; Camp S; Sticco-Ivins M; Hirsch L; Baca SC; Wind-Rotolo M; Ross-Macdonald P; Sun M; Lee GM; Chang SL; Wei XX; McGregor BA; Harshman LC; Genovese G; Ellis L; Pomerantz M; Hirsch MS; Freedman ML; Atkins MB; Wu CJ; Ho TH; Linehan WM; McDermott DF; Heng DYC; Viswanathan SR; Signoretti S; Van Allen EM; Choueiri TK
Nat Commun; 2021 Feb; 12(1):808. PubMed ID: 33547292
[TBL] [Abstract][Full Text] [Related]
23. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
24. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review.
Caccese M; Indraccolo S; Zagonel V; Lombardi G
Crit Rev Oncol Hematol; 2019 Mar; 135():128-134. PubMed ID: 30819441
[TBL] [Abstract][Full Text] [Related]
25. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitors in challenging populations.
Johnson DB; Sullivan RJ; Menzies AM
Cancer; 2017 Jun; 123(11):1904-1911. PubMed ID: 28241095
[TBL] [Abstract][Full Text] [Related]
27. A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.
Nunes-Xavier CE; Angulo JC; Pulido R; López JI
Curr Urol Rep; 2019 Jan; 20(1):1. PubMed ID: 30645700
[TBL] [Abstract][Full Text] [Related]
28. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
El Rassy E; Farhat F; Kattan J
Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
[No Abstract] [Full Text] [Related]
29. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
[TBL] [Abstract][Full Text] [Related]
30. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
31. Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: A meta-analysis.
Yang L; Liu L; Wu X; Guo X; Yang Y; Wang T
Int Immunopharmacol; 2020 Mar; 80():106148. PubMed ID: 31978802
[TBL] [Abstract][Full Text] [Related]
32. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
Harshman LC; Drake CG; Choueiri TK
Cancer Immunol Res; 2014 Dec; 2(12):1132-41. PubMed ID: 25480555
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.
Nunno VD; Nuvola G; Mosca M; Maggio I; Gatto L; Tosoni A; Lodi R; Franceschi E; Brandes AA
Immunotherapy; 2021 Apr; 13(5):419-432. PubMed ID: 33472433
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
35. Combination treatments with immunotherapy in brain metastases patients.
Henon C; Remon J; Hendriks LE
Future Oncol; 2020 Aug; 16(23):1691-1705. PubMed ID: 32412817
[TBL] [Abstract][Full Text] [Related]
36. Pushing the limits of immune-related response: a case of "extreme pseudoprogression".
Wong AS; Thian YL; Kapur J; Leong CN; Kee P; Lee CT; Lee MB
Cancer Immunol Immunother; 2018 Jul; 67(7):1105-1111. PubMed ID: 29728723
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role.
Eisen T
Eur J Cancer; 2015 Nov; 51(17):2578-9. PubMed ID: 26613659
[No Abstract] [Full Text] [Related]
38. Biomarkers to predict prognosis and response to checkpoint inhibitors.
Yuasa T; Masuda H; Yamamoto S; Numao N; Yonese J
Int J Clin Oncol; 2017 Aug; 22(4):629-634. PubMed ID: 28382562
[TBL] [Abstract][Full Text] [Related]
39. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
40. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]